SITC - SITE Centers Corp.
CHICAGO, Oct. 20, 2026 /PRNewswire/ -- Pine Tree, a national owner and operator of open-air shopping centers, announced that it has acquired sponsor interest in a 10-property portfolio recently appraised at $644 million and totaling 3.5 million square feet. The interest was acquired from SITE Centers (NYSE: SITC) in partnership with a large international investor.
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Sale of DTP Interests and Special Common Distribution.
Next generation multispecific technology designed to coordinate innate and adaptive immune activity within the tumor microenvironment SEATTLE, WA / ACCESS Newswire / October 14, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel bispecific and multispecific immunotherapies for the treatment of cancer, today announced that the Company will highlight its multispecific platform in a presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, being held November 4-8, 2026, at the Phoenix Convention Center in Phoenix, Arizona. Aptevo's presentation will feature its broader CD40-directed multispecific portfolio and the Company's approach to bringing together two critical arms of the immune system - innate and adaptive immunity - within the tumor microenvironment.
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), today announced that four abstracts featuring preclinical research from their respective immunotherapy programs have been selected for poster presentations at the Society for Immunotherapy of Cancer (SITC) 41th Anniversary Annual Meeting, taking place November 4-8, 2026, in Phoenix, AZ. The presentations will feature BriaCell's personalized off-the-shelf immunotherapy, Bria-OTS+™ and BriaPro's research on tumor-targeted checkpoint inhibitors, soluble CD80 (BP-80), and engineered CD80 variants.
Site Centers (NYSE: SITC - Get Free Report) and Deutsche Bank Aktiengesellschaft (NYSE: DB - Get Free Report) are both finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends. Insider and Institutional Ownership 88.7% of Site
![Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026](https://images.financialmodelingprep.com/news/perspective-therapeutics-announces-acceptance-of-212pbvmt01-data-for-presentation-20261002.jpg)
SEATTLE, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that data from the Company's lapemelanotide zapixetar (also known as [²¹²Pb]VMT01) program have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting & Pre-Conference Programs taking place November 4 to 8, 2026, in Phoenix, Arizona. SITC plans to release further details for regular abstracts on November 3, 2026.
Obsidian Therapeutics, Inc. (âObsidianâ) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop
[url="]Agenus Inc.[/url] (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), a
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (“Obsidian”) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today announced a poster presentation of updated data in patients with immune-checkpoint inhibitor (ICI)-resistant advanced melanoma from the Phase 1 single-center first-in-human (FIH) study and the Phase 1/2 Agni-01 multicenter study of amsoki.
NEEDHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that the Company will present data from its aglatimagene besadenovec program in non-small cell lung cancer (NSCLC) in patients with progressive NSCLC despite immune checkpoint inhibitor (ICI) treatment, as well as clinical and mechanistic findings from its phase 1b clinical trial of linoserpaturev in recurrent glioblastoma, through two accepted poster presentations at the Society for Immunotherapy of Cancer's (SITC) 41st Annual Meeting, taking place November 4-8, 2026 in Phoenix, Arizona.
- Atebimetinib enhances PD-1 checkpoint blockade in preclinical models of RAS mutant tumors - - Findings provide additional mechanistic rationale for upcoming Phase 2 study of atebimetinib in combination with PD-1 blockade in lung cancer patients - NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that a poster will be presented at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 4-8, 2026, in Phoenix, AZ, demonstrating that atebimetinib enhances PD-1 checkpoint blockade in RAS mutant tumor models. These findings support Immuneering's plans to conduct a Phase 2 study of atebimetinib in combination with PD-1 blockade in patients with lung cancer.
NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced two poster presentations at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting. The presentations address two distinct areas of cancer research: tumor-cell killing in checkpoint inhibitor–resistant colorectal cancer liver metastases and elimination of senescent tumor cells and fibroblasts.
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Sale of The Maxwell.
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Sale of Shoppes at Paradise Pointe.
Bank of New York Mellon Corp acquired a new stake in Site Centers Corp. (NYSE: SITC) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 232,031 shares of the company's stock, valued at approximately $921,000. Bank of New
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Reports Second Quarter 2026 Results.
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Sale of Meadowmont Market.
Bessemer Group Inc. increased its position in shares of Site Centers Corp. (NYSE: SITC) by 315,970.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 635,301 shares of the company's stock after acquiring an additional 635,100 shares during the period. Bessemer Group Inc.
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Sale of The Pike Outlets and Special Common Distribution.
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Reports First Quarter 2026 Results.